Gsa Capital Partners LLP Acadia Pharmaceuticals Inc Transaction History
Gsa Capital Partners LLP
- $1.19 Billion
- Q1 2024
A detailed history of Gsa Capital Partners LLP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 111,394 shares of ACAD stock, worth $1.81 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
111,394
Previous 13,407
730.86%
Holding current value
$1.81 Million
Previous $419,000
391.41%
% of portfolio
0.17%
Previous 0.04%
Shares
12 transactions
Others Institutions Holding ACAD
# of Institutions
299Shares Held
158MCall Options Held
1.88MPut Options Held
688K-
Baker Bros. Advisors LP New York, NY42.9MShares$697 Million10.04% of portfolio
-
Rtw Investments, LP New York, NY13.8MShares$225 Million4.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$216 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$190 Million0.01% of portfolio
-
State Street Corp Boston, MA6MShares$97.5 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.63B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...